We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cellectricon Announces Cellaxess-HT High Throughput Electroporation System
Product News

Cellectricon Announces Cellaxess-HT High Throughput Electroporation System

Cellectricon Announces Cellaxess-HT High Throughput Electroporation System
Product News

Cellectricon Announces Cellaxess-HT High Throughput Electroporation System


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Cellectricon Announces Cellaxess-HT High Throughput Electroporation System"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cellectricon announced collaboration with EPFL (Ecole Polytechnique Federale de Lausanne, Switzerland). EPFL is evaluating Cellectricon’s next-generation high throughput electroporation system. Cellaxess-HT is the world’s first high throughput electroporation system tailor-made for genome wide RNAi screening and will be launched Q2 2008.

"We are pleased to collaborate with EPFL and look forward to bringing this state-of-the-art system to the market.” says Dr. Mattias Karlsson, CEO at Cellectricon. “Cellaxess-HT will be the first of its kind on the market and will significantly impact drug discovery by opening the door to using more biologically relevant cell types in genome wide RNAi screening.”

“We are impressed by the unprecedented high throughput delivery of genetic materials the Cellaxess-HT system offers. We believe that Cellaxess-HT has the potential to greatly advance our efforts in our RNAi research programs”, says Dr. Gerardo Turcatti, Director of the Biomolecular Screening Facility at EP FL, Lausanne, Switzerland.

Advertisement